- Home
- FBRX vs PULM Comparison
FBRX vs PULM Comparison
Compare FBRX & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBRX
- PULM
- Stock Information
- Founded
- FBRX N/A
- PULM 2003
- Country
- FBRX United States
- PULM United States
- Employees
- FBRX N/A
- PULM N/A
- Industry
- FBRX Biotechnology: Pharmaceutical Preparations
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- FBRX Health Care
- PULM Health Care
- Exchange
- FBRX Nasdaq
- PULM Nasdaq
- Market Cap
- FBRX 8.3M
- PULM 7.4M
- IPO Year
- FBRX N/A
- PULM N/A
- Fundamental
- Price
- FBRX $15.10
- PULM $6.31
- Analyst Decision
- FBRX Strong Buy
- PULM
- Analyst Count
- FBRX 3
- PULM 0
- Target Price
- FBRX $77.58
- PULM N/A
- AVG Volume (30 Days)
- FBRX 1.5M
- PULM 1.3M
- Earning Date
- FBRX 11-14-2024
- PULM 11-08-2024
- Dividend Yield
- FBRX N/A
- PULM N/A
- EPS Growth
- FBRX N/A
- PULM N/A
- EPS
- FBRX N/A
- PULM N/A
- Revenue
- FBRX N/A
- PULM $10,005,000.00
- Revenue This Year
- FBRX N/A
- PULM N/A
- Revenue Next Year
- FBRX N/A
- PULM $1.00
- P/E Ratio
- FBRX N/A
- PULM N/A
- Revenue Growth
- FBRX N/A
- PULM 47.05
- 52 Week Low
- FBRX $4.11
- PULM $1.55
- 52 Week High
- FBRX $21.25
- PULM $8.44
- Technical
- Relative Strength Index (RSI)
- FBRX 92.83
- PULM 75.93
- Support Level
- FBRX $5.55
- PULM $5.28
- Resistance Level
- FBRX $18.81
- PULM $8.44
- Average True Range (ATR)
- FBRX 1.51
- PULM 0.98
- MACD
- FBRX 1.06
- PULM 0.39
- Stochastic Oscillator
- FBRX 78.42
- PULM 63.82
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA).
About PULM Pulmatrix Inc.
Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways.